Proteasome inhibitors for multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma treatment has evolved significantly over the past 20 years.
• The introduction of proteasome inhibitors marked a major advancement in therapy.

Purpose of the Study:

• To review recent advancements in proteasome inhibitor therapies for multiple myeloma.
• To highlight the importance of managing adverse events associated with these drugs.

Main Methods:

• Literature review of clinical studies and therapeutic strategies.
• Analysis of proteasome inhibitor properties and adverse event profiles.

Main Results:

• Proteasome inhibitors, including bortezomib, carfilzomib, and ixazomib, are now standard treatments.
• These agents are used in various combinations for newly diagnosed and relapsed/refractory multiple myeloma.
• Understanding and managing drug-specific adverse events is crucial for treatment continuity.

Conclusions:

• Proteasome inhibitors have revolutionized multiple myeloma care.
• Effective management of adverse events is essential for optimizing patient outcomes and maintaining therapeutic regimens.